Effect of CYP3A53 Polymorphism on Pharmacokinetic Drug Interaction between Tacrolimus and Amlodipine

The objective of this study was to evaluate the effect of the CYP3A5*3 allele on the pharmacokinetics of tacrolimus and amlodipine, and drug-drug interactions between them in healthy subjects. Pharmacokinetic drug interactions between tacrolimus and amlodipine were evaluated in a randomized, 3-perio...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	DRUG METABOLISM AND PHARMACOKINETICS 2013, Vol.28 (5), p.398-405
Hauptverfasser:	Zuo, Xiao-cong, Zhou, Ya-nan, Zhang, Bi-kui, Yang, Guo-ping, Cheng, Ze-neng, Yuan, Hong, Ouyang, Dong-sheng, Liu, Shi-kun, Barrett, Jeffrey S., Li, Pei-jiong, Liu, Zhi, Tan, Hong-yi, Guo, Ren, Zhou, Ling-yun, Xie, Yue-liang, Li, Zuo-jun, Li, Jing, Wang, Chun-jiang, Wang, Jiang-lin
Format:	Artikel
Sprache:	eng
Schlagworte:	amlodipine Amlodipine - pharmacokinetics CYP3A53 polymorphism Cytochrome P-450 CYP3A - genetics Drug Interactions drug-drug interaction Humans Immunosuppressive Agents - pharmacokinetics Male pharmacokinetics Polymorphism, Single Nucleotide tacrolimus Tacrolimus - administration & dosage Tacrolimus - pharmacokinetics Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!